Moderna (MRNA) Tops Q1 EPS by $3.37, Revenue Beats

Moderna (NASDAQ: MRNA) reported Q1 EPS of $8.58, $3.37 better than the analyst estimate of $5.21. Revenue for the quarter came in at $6.1 billion versus the consensus estimate of $4.62 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c